Policy statements
In circumstances when NHS England needs to implement a commissioning policy quickly, a Policy Statement or Urgent Policy Statement will be developed. These policy statements have been through the standard development process for all policies, including evidence review, impact analysis and decision by the Clinical Priorities Advisory Group (CPAG), however they have not been subject to public consultation. Once the policy statement is published, a full clinical commissioning policy may be developed.
Routinely commissioned:
- Active middle ear implants
- Alemtuzumab for treating relapsing-remitting multiple sclerosis – third cycle (all ages)
- Allogeneic stem cell transplantation for adults with PID disorders
- Biologic therapies for the treatment of juvenile idiopathic arthritis
- Docetaxel in combination with androgen deprivation therapy for the treatment of hormone naïve metastatic prostate cancer
- Everolimus (Votubia®) for treatment of angiomyolipomas associated with tuberous sclerosis
- Flow diverting devices for intracranial aneurysms
- Nusinersen for genetically confirmed spinal muscular atrophy Type 1 for eligible patients under the expanded access programme
- Pembrolizumab for drug-resistant gestational trophoblastic neoplasia
- Prenatal surgery for open spina bifida
- Retreatment of Chronic Hepatitis C infection in adults with advanced or decompensated cirrhosis
- Rituximab biosimilar for the treatment of myasthenia gravis (adults)
- Rituximab for the treatment of systemic lupus erythematosus in adults
- Stereotactic radiosurgery / radiotherapy for ocular melanoma and pituitary adenoma
- Stereotactic Radiosurgery and Stereotactic Radiotherapy for Primary Non-Germ Cell Pineal Tumours (All Ages)
- Stereotactic Radiosurgery and Stereotactic Radiotherapy for Intracranial Ependymoma (Children)
- Teriparatide for osteoporosis in men (adults)
Not for routine commissioning:
- Arsenic trioxide for the treatment of high risk acute promyelocytic leukaemia
- Cerebellar stimulator implants
- Cerliponase alfa for neuronal ceroid lipofuscinosis Type 2 in children
- Convection enhanced delivery for diffuse intrinsic glioma
- Deep brain stimulation for indications except movement disorders
- Eculizumab in the prevention of recurrence of C3 glomerulopathy post kidney transplant
- Natalizumab-induced progressive multifocal leukoencephalopathy in relation to immune reconstitution inflammatory syndrome in multiple sclerosis
- Patent foramen ovale closure
- Percutaneous mitral valve leaflet repair for mitral regurgitation
- Selective internal radiotherapy (SIRT)
- Sphenopalatine Ganglion Stimulation for Refractory, Chronic Cluster Headache (adults)
- Surgical treatment for women who have undergone female genital mutilation